Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB known ✓ | P27338 | 10/20 | 0.46 |
| ▸ | HRH3 known ✓ | Q9Y5N1 | 1/20 | 0.42 |
| ▸ | F11 | P03951 | 1/20 | 0.54 |
| ▸ | ST14 | Q9Y5Y6 | 3/20 | 0.48 |
| ▸ | ABAT | P80404 | 1/20 | 0.44 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.41 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.40 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3591237 | 0.98 | ST14 (0.50) | F11ST14MAOBABATHRH3 | |
| SCHEMBL28067255 | 0.96 | ST14 (0.48) | F11ST14MAOBABATHRH3 | |
| SCHEMBL28069904 | 0.92 | HRH3 (0.56) | F11ST14MAOBABATHRH3 | |
| SCHEMBL29278208 | 0.87 | ST14 (0.41) | F11ST14MAOBABATHRH3 | |
| SCHEMBL29112149 | 0.81 | TAAR1 (0.55) | MAOB | |
| Hydrochloric Acid SCHEMBL28156681 | 0.80 | ENPP2 (0.47) | F11MAOBLOXL2 | |
| SCHEMBL3800806 | 0.78 | CA1 (0.38) | — | |
| SCHEMBL29643534 | 0.78 | ENPP2 (0.48) | F11ST14MAOBLOXL2 | |
| SCHEMBL27569009 | 0.78 | ENPP2 (0.48) | F11ST14MAOBLOXL2 | |
| SCHEMBL1251529 | 0.77 | LTA4H (0.50) | HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024169871-A1 | BTK INHIBITOR AND USE THEREOF | 江苏威凯尔医药科技有限公司 | 2024-08-22 | — | — | WO | disclosed |
| WO-2023165570-A1 | CYCLOALKYL OR HETEROCYCLYL SUBSTITUTED HETEROARYL COMPOUND, AND COMPOSITION AND USE THEREOF | 深圳市塔吉瑞生物医药有限公司 | 2023-09-07 | — | — | WO | disclosed |
| US-20230192691-A1 | HETEROCYCLIC COMPOUNDS AS BTK INHIBITORS | BEIJING INNOCARE PHARMA TECH CO LTD (CN) | 2023-06-22 | — | — | US | disclosed |
| CN-116113406-A | GAS41 inhibitors and methods of use thereof | 密歇根大学董事会 | 2023-05-12 | — | — | CN | disclosed |
| CN-114920690-A | Amide derivative and application thereof in medicine | 四川海思科制药有限公司 | 2022-08-19 | — | — | CN | disclosed |
| CN-105732665-B | Asymmetric pyrrolobenzodiazepine-dimers for use in the treatment of proliferative diseases | 医疗免疫有限公司 | 2021-06-04 | — | — | CN | disclosed |
| CN-105732666-B | Asymmetric pyrrolobenzodiazepine-dimers for use in the treatment of proliferative diseases | 医疗免疫有限公司 | 2020-08-21 | — | — | CN | disclosed |
| CN-106661035-B | The Pyrazolopyrimidine derivative of inhibitor as bruton's tyrosine kinase | 洛克索肿瘤学股份有限公司 | 2019-11-19 | — | — | CN | disclosed |
| CN-104684899-B | Substituted sulfonamide compounds | 霍夫曼-拉罗奇有限公司 | 2017-07-04 | — | — | CN | disclosed |
| CN-106661035-A | Pyrazolopyrimidine derivatives as inhibitors of bruton's tyrosine kinase | 莱德克斯制药公共有限公司 | 2017-05-10 | — | — | CN | disclosed |
| EP-1582250-B1 | Absorbent with improved oxidation resistance and process for deacidifying fluid fluxes | BASF SE (DE) | 2013-05-15 | — | — | EP | disclosed |
| US-7666813-B2 | an aliphatic amine, in particular an alkanolamine, and a non-hydroquinoid antioxidant for removal of CO2, H2S, SO2, CS2, HCN, COS, disulfides or mercaptans as impurities in reaction gases formed in the oxidation of organic materials to prevent the emission of above gases | BASF AKTIENGESELLSCHAFT (DE) | 2010-02-23 | — | — | US | disclosed |
| EP-1582250-A2 | Absorbent with improved ocidation resistance and process for deacidifying fluid fluxes | BASF AKTIENGESELLSCHAFT (DE) | 2005-10-05 | — | — | EP | disclosed |
| US-20050202967-A1 | an aliphatic amine, in particular an alkanolamine, and a non-hydroquinoid antioxidant for removal of CO2, H2S, SO2, CS2, HCN, COS, disulfides or mercaptans as impurities in reaction gases formed in the oxidation of organic materials to prevent the emission of above gases | BASF AKTIENGESELLSCHAFT (DE) | 2005-09-15 | — | — | US | disclosed |
| US-4264738-A | ABSORPTION BY THE PRODUCT OF AN AMINO DERIVATIVE OF A SILICEOUS MATERIAL, A CONDENSATION AGENT, AND A LIGAND | STEPANOV VALENTIN M | 1981-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230192691-A1 | HETEROCYCLIC COMPOUNDS AS BTK INHIBITORS | BTK, SYK, LYN | MAOB 1225/4885HRH3 1501/4885F11 470/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.